Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics

22 Dec 2021

Abstract excerpt

-(2-butoxyphenyl)-3-(phenyl)acrylamides (N23Ps) as a novel and highly potent compound class. N23Ps suppressed myofibroblast transdifferentiation, ECM deposition, cellular contractility, and altered cell shapes, thus advocating a unique mode of action. Mechanistically, transcriptomics identified SMURF2 as a potential therapeutic target network. Antifibrotic activity of N23Ps was verified by proteomics in a human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Occupational and environmental lung diseases
Share to Occupational exposure and asthma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34936468
DOI: 10.1126/sciadv.abb3673

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeuticsPMID 34936468Read ↗

Drug Repurposing Through a Bioinformatics Pipeline Applied on Fibrotic DiseasesSemantic proximity Read ↗

Shared and distinct mechanisms of fibrosis.Semantic proximity Read ↗

CCN3-derived peptide BLR-200 impairs YAP activation and attenuates bleomycin-induced skin fibrosis through blocking the generation of Sfrp2-positive fibroblastsSemantic proximity Read ↗

Stage-Dependent Fibrotic Gene Profiling of WISP1-Mediated Fibrogenesis in Human FibroblastSemantic proximity Read ↗

FLECS Technology for High-Throughput Screening of Hypercontractile Cellular Phenotypes in Fibrosis: A Function-First Approach to Anti-Fibrotic Drug DiscoverySemantic proximity Read ↗

FLECS technology for high-throughput screening of hypercontractile cellular phenotypes in fibrosis: A function-first approach to anti-fibrotic drug discovery.Semantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.Semantic proximity Read ↗

A noble TGFβ biogenesis inhibitor exhibits both potent anti-fibrotic and anti-inflammatory capabilitiesSemantic proximity Read ↗

Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosisSemantic proximity Read ↗

Single cell transcriptomics in a treatment-segregated cohort exposes a STAT3-regulated therapeutic gap in idiopathic pulmonary fibrosisSemantic proximity Read ↗

Transcriptomic Profiling of Primary Human Dermal Fibroblasts Response to Perlatolic Acid and BromoatranorinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.